top of page

3D Global Biotech and YD Biopharma Forge Strategic Partnership to Drive Biotech Innovation



On June 19, 2024, 3D Global Biotech announced a significant patent licensing agreement with its major shareholder, YD Biopharma. The agreement grants YD Biopharma the exclusive rights to utilize 3D Global Biotech’s cutting-edge corneal limbal stem cell (LSCs) technology. In return, YD Biopharma will pay an initial signing fee of USD 1 million, with the potential for an additional USD 4 million in milestone payments as various stages of research and development are completed.


Founded in December 2014, 3D Global Biotech has been at the forefront of developing advanced 3D bioprinting technology and customized autologous cell-based medical products. As a leader in Taiwan’s international biotech landscape, 3D Global Biotech has solidified its technological edge through this collaboration with YD Biopharma, further expanding its global market influence. This patent licensing agreement marks a new milestone for both companies in the biomedical technology and medical device markets.


Since its establishment in 2013, YD Biopharma has evolved from operating pharmacies to focusing on pharmaceutical operations and medical equipment supply. With its expertise in clinical trials and the development of innovative therapies, YD Biopharma has earned widespread recognition within the industry. The collaboration with 3D Global Biotech signifies YD Biopharma’s continued expansion in the field of innovative medical technology, particularly in corneal disease treatment and pancreatic cancer detection.


This partnership not only enhances the brand value of both 3D Global Biotech and YD Biopharma but also heralds new possibilities in the biotech sector. As the technology is further commercialized and integrated into market operations, both companies are committed to improving patient outcomes and advancing global medical technology.

Comments


Commenting has been turned off.
bottom of page